


JEEVAN SCIENTIFIC TECHNOLOGY LIMITED
Registered Office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad-500008.
STANDALONE UN AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2019

Sl.No	Particulars	Rupees in Lakhs				
		Quarter Ended			Nine Months Ended	
		31-12-2019 Un Audited	30-09-2019 Un Audited	31-12-2018 Un Audited	31-12-2019 Un Audited	31-12-2018 Un Audited
						Previous Year Ended 31-03-2019 Audited
1	Income					
	(a) Revenue From Operations	726.55	482.43	783.25	1500.06	2,120.40
	(b) Other Income	37.32	28.36	10.09	90.98	88.85
	Total income	763.87	510.79	793.34	1,591.04	2,209.25
2	Expenses					
	(a) Cost of Material Consumed	40.97	38.98	59.75	117.73	138.76
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefit expense	209.95	207.77	223.47	614.36	602.79
	(e) Finance Cost	55.98	62.25	49.75	175.39	137.49
	(f) Depreciation and Amortisation expense	99.77	99.72	87.68	297.74	238.46
	(g) Other Expenses	281.52	267.09	247.62	736.13	776.90
	Total Expenses	688.19	675.81	668.27	1,941.35	1,894.40
3	Profit before exceptional items and Tax	75.68	-165.02	125.07	-350.31	314.85
4	Add(+)/Less(-) Exceptional items	-	-	-	-	-
5	Profit before Tax	75.68	-165.02	125.07	-350.31	314.85
6	Tax Expenses	-23.05	34.53	38.36	68.99	38.56
7	Profit(Loss) for the Period from Continuing Operations	52.63	-130.49	86.71	-281.32	276.29
8	Profit(Loss) from Discontinuing Operations	-	-	-	-	-
9	Tax Expenses on discontinuing Operations	-	-	-	-	-



Sl.No	Particulars	Quarter Ended			Nine Months Ended		Previous Year
		31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	31-03-2019
		Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	Audited
10	Profit(Loss) from Discontinuing Operations after Tax	-	-	-	-	-	-
11	Profit(Loss) for the period	52.63	-130.49	86.71	-281.32	276.29	135.95
12	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	0.98	-8.09	0.25	-6.77	0.75	1.94
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-0.11	-	-0.21	-0.54
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
13	Total Comprehensive Income for the period	53.61	-138.58	86.85	-288.09	276.83	137.35
14	Paid Up Equity Share Capital (Face Value of Rs.10/- each)	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15	1,530.15
15	Other equity excluding revaluation reserve						1,746.73
16	Earnings per Equity share (for continuing operations)						
	a) Basic (Amount in Rupees)	0.35	-0.91	0.57	-1.88	1.81	0.90
	b) Diluted (Amount in Rupees)	0.35	-0.91	0.57	-1.88	1.94	0.94
17	Earnings per Equity share (for discontinued operations)						
	a) Basic (Amount in Rupees)	-	-	-	-	-	-
	b) Diluted (Amount in Rupees)	-	-	-	-	-	-
18	Earnings per Equity share (for Continuing & discontinued operations)						
	a) Basic (Amount in Rupees)	0.35	-0.91	0.57	-1.88	1.81	0.90
	b) Diluted (Amount in Rupees)	0.35	-0.91	0.57	-1.88	1.94	0.94

Notes to the Standalone Un Audited Financial Results

- The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015
- The above results have been reviewed by the Audit Committee at its meeting held on 14.02.2020 and approved by the Board of Directors of the Company on the same date. These Results are also subjected to Limited Review by the Company's Statutory Auditors.
- During the year Company is operating in only one segment i.e., Clinical Research Services
- The Company has adopted Ind As-116, effective annual reporting period beginning April 1, 2019 and applied the standard to its leases. However, there is no impact on the financials of the company.
- Figures for the previous periods have been rearranged wherever necessary.

Place:Hyderabad
Date:14.02.2020



SEGMENT-WISE REVENUE, RESULTS & CAPITAL EMPLOYED (Stand Alone Unaudited)
UNDER CLAUSE 41 OF THE LISTING AGREEMENT FOR THE QUARTER ENDED 31ST DECEMBER, 2019

Particulars	Quarter Ended			Nine Months Ended		Rupees in Lakhs
	31-12-2019	30-09-2019	31-12-2018	31-12-2019	31-12-2018	Previous Year
	Un Audited	Un Audited	Un Audited	Un Audited	Un Audited	31-03-2019 Audited
SEGMENT REVENUE: (Net Sales / Income from Operations)						
a) Clinical Research Services	763.87	510.79	783.25	1591.04	2,120.40	2,636.87
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	-	-	-	-	-	-
d) Unallocable income	-	-	10.09	-	88.85	-
Total:	763.87	510.79	793.34	1,591.04	2,209.25	2,636.87
LESS: Inter Segment revenue	-	-	-	-	-	-
Net Sales / income from Operations.	763.87	510.79	793.34	1,591.04	2,209.25	2,636.87
SEGMENT RESULTS : PROFIT / (LOSS) BEFORE TAX AND INTEREST						
a) Clinical Research Services	131.66	-102.77	164.73	-174.92	363.49	333.12
b) Information Technology Services	-	-	-	-	-	-
c) Data Management Services	-	-	-	-	-	-
Total:	131.66	-102.77	164.73	-174.92	363.49	333.12
LESS:						
i) Interest	55.98	62.25	49.75	175.39	137.49	171.14
ii) Other Un-Allocable Expenditure	-	-	-	-	-	-
iii) Un-Allocable Income	-	-	-10.09	-	-88.85	-
TOTAL PROFIT /(-LOSS) BEFORE TAX	75.68	-165.02	125.07	-350.31	314.85	161.98

Place: Hyderabad
Date: 14.02.2020

for Jeevan Scientific Technology Limited
On behalf of the Board of Directors

K. Krishna Kishore
Vice Chairman & Managing Director

